TREA

79207192 - HUMABFC

Follow

Information

  • Trademark
  • 79207192
  • Serial Number
    79207192
  • Registration Number
    5510331
  • Filing Date
    December 14, 2016
    8 years ago
  • Registration Date
    July 10, 2018
    6 years ago
  • Transaction Date
    February 18, 2025
    5 days ago
  • Status Date
    January 24, 2025
    a month ago
  • Published for Opposition Date
    April 24, 2018
    6 years ago
  • Location Date
    July 10, 2018
    6 years ago
Information
Mark Drawing Code
4
Mark Identification
HUMABFC
Case File Statements
  • GS0051: Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing
  • GS0421: Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies
Case File Event Statements
  • 5/11/2017 - 7 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 5/13/2017 - 7 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 5/13/2017 - 7 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/13/2017 - 7 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/14/2017 - 7 years ago
    5 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 5/17/2017 - 7 years ago
    6 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 5/23/2017 - 7 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 5/23/2017 - 7 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 11/14/2017 - 7 years ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 6/10/2017 - 7 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 10/24/2017 - 7 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/3/2017 - 7 years ago
    11 - ASSIGNED TO LIE Type: ALIE
  • 11/14/2017 - 7 years ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/11/2017 - 7 years ago
    14 - FINAL REFUSAL WRITTEN Type: CNFR
  • 12/11/2017 - 7 years ago
    15 - FINAL REFUSAL E-MAILED Type: GNFR
  • 12/11/2017 - 7 years ago
    16 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 3/5/2018 - 6 years ago
    17 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 3/5/2018 - 6 years ago
    18 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/6/2018 - 6 years ago
    19 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/17/2018 - 6 years ago
    20 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 4/4/2018 - 6 years ago
    21 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 4/4/2018 - 6 years ago
    22 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 4/4/2018 - 6 years ago
    23 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 4/20/2018 - 6 years ago
    24 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 4/24/2018 - 6 years ago
    26 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 7/10/2018 - 6 years ago
    27 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 10/10/2018 - 6 years ago
    28 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 10/16/2018 - 6 years ago
    29 - GENERIC MADRID TRANSACTION CREATED Type: XXCR
  • 10/16/2018 - 6 years ago
    30 - GENERIC MADRID TRANSACTION SENT TO IB Type: XXSS
  • 12/21/2018 - 6 years ago
    31 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 3/5/2021 - 3 years ago
    32 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 4/3/2021 - 3 years ago
    33 - CORRECTION TRANSACTION RECEIVED FROM IB Type: CRCV
  • 4/6/2021 - 3 years ago
    34 - CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED Type: CORN
  • 7/10/2023 - a year ago
    36 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 1/24/2025 - a month ago
    38 - CANCELLED SECTION 71 Type: C71T
  • 5/4/2024 - 9 months ago
    37 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 4/24/2018 - 6 years ago
    25 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 4/9/2021 - 3 years ago
    35 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP